The Menopause Care Gap: A Shortage on Top of a Shortage The estrogen patch shortage is making headlines, but its layered on top of a deeper structural problem: the menopause care gap itself
Contraindicated groups: Pregnant women, lactating women and children are prohibited from using it
870, Oct
Discover eternal youth.
Pre-approving information
Exogenous AAS inhibit endogenous testosterone production, and discontinuation of their use is often associated with a prolonged decrease in testosterone secretion ( The substances used in PCT are administered in the treatment of male hypogonadism unrelated to androgen abuse ( To restore endogenous testosterone, mainly aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and human chorionic gonadotropin (hCG) are used ( In the 2024 WADA Prohibited List ( Aromatase is an enzyme that converts testosterone to estradiol (the most potent estrogen form) and androstenedione to estrone ( The anti-estrogenic compounds mentioned in the WADA list can be divided into two groups: SERMs (bazedoxifene, clomiphene, cyclofenil, ospemifene, raloxifene, tamoxifen, and toremifene) and selective estrogen receptor degraders (SERDs), of which fulvestrant is a representative
.webp)
